Medroxyprogesterone 17-Acetate (Depo-Provera)

1530  relevant articles (92 outcomes, 295 trials/studies) found for this Drug

Depo-Provera; Medroxyprogesterone Acetate; Provera; Curretab; Cycrin; Acetate, Medroxyprogesterone; DepoProvera; (6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione; 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate; Clinovir; Farlutal; Gestapuran; Medroxyprogesterone 17-Acetate, (6 alpha,17 alpha)-Isomer; Medroxyprogesterone 17-Acetate, (6 beta)-Isomer; Perlutex; Veramix; 17-Acetate, Medroxyprogesterone; 6 alpha Methyl 17alpha hydroxyprogesterone Acetate; Acetate, 6-alpha-Methyl-17alpha-hydroxyprogesterone; Acetate, Depo-Medroxyprogesterone; Depo Medroxyprogesterone Acetate; Depo Provera; Medroxyprogesterone 17 Acetate; Depo-Medroxyprogesterone Acetate; Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-

Relationship Network

Drug Context: Research Results

Experts

1.	Kawaguchi, M: 3 articles (01/2006 - 01/2001)
2.	Kuramoto, H: 3 articles (01/2006 - 01/2001)
3.	Jobo, T: 3 articles (01/2006 - 01/2001)
4.	Madeddu, Clelia: 3 articles (07/2003 - 05/2002)
5.	Mantovani, Giovanni: 3 articles (07/2003 - 05/2002)
6.	Massa, Elena: 3 articles (07/2003 - 05/2002)
7.	Macciò, Antonio: 3 articles (07/2003 - 05/2002)
8.	Elovitz, Michal A: 2 articles (04/2008 - 09/2005)
9.	Pickar, James H: 2 articles (08/2007 - 05/2004)
10.	Jassem, J: 2 articles (12/2006 - 08/2004)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/1998 - "We herein report the case of a patient with recurrent breast cancer who showed a remarkable improvement in her quality of life (QOL) as a result of a good response to medroxyprogesterone acetate (MPA)" 01/01/1998 - "Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care." 08/01/2000 - "Treatment of advanced or recurrent breast cancer with medroxyprogesterone acetate (MPA) shows high response rates and the accessory effects of appetite stimulation, improvement in performance status (PS) and bone marrow protection" 12/01/1987 - "Low dose oral medroxyprogesterone acetate is as effective as high dose therapy in the treatment of advanced breast cancer, and is cheaper and less toxic." 10/31/1979 - "MPA) Medroxyprogesterone acetate when employed at high doses (5001000 mg/day intramuscularly) can produce objective remission with improved survival in about 30% of postmenopausal women with advanced breast cancer resistant to cytotoxic drugs and endocrine therapies" Order ALL the reference details at left...
2.	Endometriosis (Adenomyosis) 09/01/1988 - "In summary, oral medroxyprogesterone acetate is effective in relieving symptoms and objectively improving endometriosis" 03/01/1976 - "Efficacy of oral medroxyprogesterone acetate (MPA) was assessed in 35 women with an established diagnosis of endometriosis (33 pelvic and 2 abdominal)" 07/01/2000 - "OBJECTIVE: To determine the efficacy of medroxyprogesterone acetate (MPA), 50 mg/d for 3 months, in treating endometriosis, with a follow-up of 6 months" 03/01/2000 - "The efficacy of depot medroxyprogesterone acetate in the treatment of endometriosis was assessed in 19 patients with severe diseases" 03/01/2006 - "Newer options for treatment of endometriosis include depot medroxyprogesterone acetate subcutaneous injection, as well as several agents under investigation that may prove to have therapeutic potential." Order ALL the reference details at left...
3.	Neoplasms (Cancer) 10/01/1986 - "All 101 patients who simultaneously had ERC and PRC in concentrations higher than 30 fmol/mg protein remained disease free for 2 years, whereas all recurrences in patients with receptor-poor tumors appeared during the 2 years of medroxyprogesterone acetate treatment" 04/01/2006 - "Medroxyprogesterone acetate (200 mg/day) was effective in one RCT, particularly in patients with well-differentiated, receptor-positive tumors" 02/01/1998 - "Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial." 05/20/1989 - "At the doses used in this study, however, no inhibitory effect on tumor growth or synergism between medroxyprogesterone acetate and CDDP was observed" 07/01/1986 - "Rectal administration of medroxyprogesterone acetate in cancer patients: a pharmacokinetic study." Order ALL the reference details at left...
4.	Hemorrhage 10/01/2004 - "Following a period of 6 months after the initiation of Depo Provera, 30% became amenorrhoeic, 70% noticed improvement in their bleeding pattern and 15% had an increase in their haemoglobin levels" 08/01/2000 - "In the current study, endometrial biopsies were sampled from bleeding (BL) and non-bleeding (NBL) sites under camera-directed hysteroscopic guidance after Depo-provera injections" 07/01/1995 - "In the first study, researchers learned that giving early second injections of Depo-Provera to adolescents did not affect their bleeding patterns and increased the body mass index (BMI) two-fold (e.g., BMI at 3 months, 0.4 vs. 0.99)" 10/01/2006 - "Cessation of bleeding had occurred in 88% of the OC group and 76% of those receiving medroxyprogesterone acetate, with a median time to bleeding cessation of 3 days for both groups" 09/01/2006 - "Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg." Order ALL the reference details at left...
5.	Endometrial Neoplasms (Endometrial Cancer) 06/01/1999 - "Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group." 12/01/1991 - "Based on a pilot study, an open, randomized, crossover trial has been performed on 22 breast and endometrial cancer patients to evaluate the relative bioavailability of this new oral formulation (200-mg sachet, twice daily) as compared with a standard formulation (Farlutal, 500-mg tablet, twice daily)" 04/01/1981 - "The study by McDaniel and Potts of women with endometrial cancer hospitalized in Chiang Mai and Lumpoon Provinces which examined Depo-Provera use among them had too small a sample to detect less than a 20-fold relative risk; moreover, very few cases of endometrial cancer actually came in for treatment" 04/01/2007 - "METHODS: Ishikawa endometrial carcinoma cells were cultured for a long period (10 months) in the presence of the synthetic progestin medroxyprogesterone acetate (MPA), thereby generating a subline refractory to the growth-suppressive effects of MPA" 06/01/2003 - "High-dose medroxyprogesterone acetate therapy combined with assisted reproductive technology resulted in pregnancy in 1 of the 2 patients with endometrial carcinoma" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Medroxyprogesterone 17-Acetate (Depo-Provera)
2.	Estrogens (Estrogen)
3.	Tamoxifen
4.	N,N-dimethyl-4-anisidine (DMPA)
5.	Conjugated (USP) Estrogens (Premarin)
6.	Megestrol Acetate (Borea)
7.	Estradiol (Estrace)
8.	Progestins (Progestagens)
9.	Gonadotropin-Releasing Hormone (GnRH)
10.	Hormones

Related Therapies and Procedures

1.	Contraception (Birth Control)
2.	Estrogen Replacement Therapy
3.	Intrauterine Devices (Intrauterine Device)
4.	Drug Therapy (Chemotherapy)
5.	Hormone Replacement Therapy (Therapy, Hormone Replacement)